OTP-01 (Jankistomig), A Unique Dual Paratopic Antibody that Bifunctionally Inhibits PD-1 and VEGFR2
- Structural differentiation: Unlike head-to-tail bispecifics, OTP-01 is a standard effector-null IgG1 that possesses a unique dual-paratopic Fab with overlapping binding sites that co-engage PD-1 and VEGFR2 in a single arm
- Functional differentiation: Leveraging a standard IgG1 backbone, OTP-01 potently and cooperatively engages both targets to enhance tumor biodistribution, while simultaneously neutralizing – VEGF-A/C/D signalling to optimally remodel the TME and curb resistance
- Clinical trajectory: OTP-01 is now in IND-enabling studies, with IND submission targeted for late 2025